This drug was tested in a Phase II study (NCI Clinical Trial NCT00557609) examining the drug's effect on Microphthalmia Transcription Factor Family (MiT) tumors, which include ASPS, clear cell carcinoma, and renal cell carcinomas bearing a TFE3 translocation [41]. This evidence concerns the gene TFE3 and hereditary clear cell renal cell carcinoma.